Unknown

Dataset Information

Development and validation of a mutation-based model to predict immunotherapeutic efficacy in NSCLC.


ABSTRACT:

Background

Immunotherapy has become increasingly important in the perioperative period of non-small-cell lung cancer (NSCLC). In this study, we intended to develop a mutation-based model to predict the therapeutic effificacy of immune checkpoint inhibitors (ICIs) in patients with NSCLC.

Methods

Random Forest (RF) classifiers were generated to identify tumor gene mutated features associated with immunotherapy outcomes. Then the best classifier with the highest accuracy served for the development of the predictive model. The correlations of some reported biomarkers with the model were analyzed, such as TMB, PD-(L)1, KEAP1-driven co-mutations, and immune subtypes. The training cohort and validation cohorts performed survival analyses to estimate the predictive efficiency indepe

SUBMITTER: He P 

PROVIDER: S-EPMC9998990 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature